Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar in Patients With FSGS Undergoing Renal Transplant
NCT02683889Phase 3Completed
- Sponsor
- University of Colorado Denver
- Start
- Feb 2019
- Primary completion
- Jun 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of corticotropin in focal segmental glomerulosclerosis (FSGS), sponsored by University of Colorado Denver. Primary endpoints: Rate of Recurrence of Focal Segmental Glomerulosclerosis as Seen in Renal Transplant Biopsies at 2 years and Rate of Recurrence of Proteinuria at 2 years. Started Feb 2019; status: completed.
02
Drugs
corticotropin
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT02683889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683889.